Jacob Moyer, BS
Advertisement
Jacob Moyer, BS, is a graduate researcher at Mayo Clinic.
Articles by Jacob Moyer, BS
Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.
Advertisement
Latest Updated Articles
Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBCPublished: March 19th 2025 | Updated:
Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPHPublished: May 1st 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5